TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, male Caucasians between 18 and 45 years of age, inclusive~* Normotensive subjects (systolic BP \<140 mmHg and diastolic BP \<90 mmHg)~* Body mass index (BMI) 19-27, minimal weight 60 kg~* Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests, and negative result in anti-ß1-receptor-autoantibody screening~* Signed Informed Consent Form~* Normal or clinically irrelevant laboratory findings~Exclusion Criteria:~* Autoimmune disorders~* Kidney diseases~* Liver diseases, liver function impairments

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- COR-1 (Type: ACTIVE_COMPARATOR): single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
- placebo (Type: PLACEBO_COMPARATOR): intravenous 0.9 % NaCl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has T2DM and is on acarbose alone at a stable dose of at least 50 mg t.i.d.(three times a day) for at least 10 weeks or on acarbose at a stable dose of at least 50 mg t.i.d. (three times a day) for at least 10 weeks in combination with another antihyperglycemic agent (AHA)~* is at least 18 years of age (for participants in India: between 18 and 65 years of age)~* male or female who is unlikely to conceive (not of reproductive potential, or agrees to remain abstinent or use \[or have partner use\] acceptable birth control if of reproductive potential)~Exclusion Criteria:~* has a history of type 1 diabetes mellitus~* use of thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or insulin~* has the following cardiovascular disorders: acute coronary syndrome; new or worsening symptoms of coronary heart disease; coronary artery intervention; stroke or transient ischemic neurological disorder~* has liver or kidney disease~* has cancer or any clinically significant disease or disorder as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily \[t.i.d.\])
- Placebo (Type: PLACEBO_COMPARATOR): Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypertonic Saline Solution in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years old~* Heart failure according to Framingham criteria~* Episode of acute decompensation,with need of in-hospital treatment~* Presence of congestive phenomena~Exclusion Criteria:~* Patient denial~* Left-ventricle ejection fraction over 0,4, as measure by transthoracic echocardiography~* Rheumatic disease~* Restrictive cardiomyopathy~* Alcohol abuse~* Chronic obstructive pulmonary disease~* Cancer~* Pulmonary embolism during the last 6 months~* Surgical procedures or acute illness during the last 30 days~* Chronic or acute infection~* Any other circumstance that may hamper patient prognosis for the next 6 months~* Serum creatine over 3.0mg/dL~* Serum potassium over 5.5 mEqs/L~* Any specific condition associated to the acute episode of decompensation, such as new onset cardiac arrhythmias, heart ischemia, infection, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
- B (Type: PLACEBO_COMPARATOR): Group of patients that will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has primary Type II hyperlipidemia or mixed dyslipidemia.~* If the patient is currently taking a lipid modifying medication other than Zocor \& he/she is willing to discontinue this medication~* LDL-C levels and/or non HDL-C levels above normal.~* Reasonable compliance with a standard cholesterol-lowering diet for a minimum of 4 weeks prior to screening and for the duration of the study.~Exclusion Criteria:~* Patient has an allergy, hypersensitivity, or intolerance to niacin, statins, or their derivatives.~* HbA1c ≥ 9% in diabetic patients

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gene Regulation by Thiazolidinediones

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of giving informed consent~* Agrees to use a barrier method of birth control for the duration of the study~Exclusion Criteria:~* History of inflammatory bowel disease~* Has taken prescription or over the counter medications in the two weeks prior to enrollment~* History of diabetes, heart failure, angina, hypertension, coronary heart disease, cancer, bleeding disorder, HIV, AIDS~* Fasting LDL \>160 mg/dl~* History of smoking in the year prior to enrollment~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Rosiglitazone (Type: OTHER): Rosiglitazone; 8mg tablet once a day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ocular hypertension or primary open-angle glaucoma in each eye~* Requires treatment with IOP-lowering medication in both eyes~Exclusion Criteria:~* Required chronic use of ocular medications during the study other than study medication~* Use of any corticosteroids within 30 days~* History of any prior eye surgery, except for uncomplicated eye surgery performed more than 6 months before the Screening visit~* Anticipated wearing of contact lenses during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Combination Therapy (Type: EXPERIMENTAL): Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
- Combigan® (Type: ACTIVE_COMPARATOR): Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to Grady Memorial Hospital who meet diagnosis criteria of DKA and who are willing to participate in the study protocol will be considered candidates for inclusion into the study.~* Diagnostic Criteria for DKA: Blood glucose \> 250 mg/dL, arterial or venous phenol hydroxylase (pH) \< 7.3, serum bicarbonate \< 18 milliequivalent/L, and moderate to severe ketonemia (acetoacetate ≥ 1:4 or βeta-hydroxybutyrate \> 3 mmol).~Exclusion Criteria:~* Hemodynamic instability (MAP \< 50 or patients requiring pressor)~* Significant identifiable medical or surgical illness, including but not limited to: acute myocardial infarction, congestive heart failure; respiratory failure requiring mechanical ventilation; acute or chronic renal insufficiency (serum creatinine \> 3.0 mg/dl); end stage liver failure, and cirrhosis.~* Patients with dementia or persistent altered mental status that would prevent collection of consent form and reliable information.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine+glulisine (Type: EXPERIMENTAL): Daily insulin glargine + glulisine before meals
- Split-mixed NPH + Regular insulin (Type: ACTIVE_COMPARATOR): Split-mixed NPH + Regular insulin twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mask Ventilation Before and After Neuromuscular Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 18 years or greater~* Present for elective surgery and~* Require placement of a breathing tube for their surgery~Exclusion Criteria:~* Patients will not be eligible if they are pregnant~* Are a minor~* Are a prisoner~* Have impaired decision-making capacity~* Have symptomatic untreated reflux~* Prior esophagectomy or hiatal hernia~* Vomiting within 24 hours of surgery~* Known oral or facial pathology making a proper mask fit unlikely~* Any condition for which the primary anesthesia team deems a rapid-sequence intubation to be appropriate~* Prior allergy or contraindication to receiving rocuronium, vecuronium, or succinylcholine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Post-induction (Type: OTHER): Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 4 Hepatitis C virus (HCV) infection (confirmed at screening)~* Plasma HCV ribonucleic acid (RNA) of \>10,000 IU/mL at screening~* Participants should be either treatment-naïve or treatment-experienced (non-responder or relapser) with adequate documentation of previous response~* Participants must have voluntarily signed an Informed Consent Form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. To participate in the optional pharmacogenomic component in this study (exploratory host genotyping), participants must have voluntarily signed a separate ICF for this component (where local regulations permit). Refusal to give consent for this component does not exclude a participant from participation in the core study.~* Participants must have had a liver biopsy within 3 years prior to screening (or between screening and baseline visit) with histology consistent with chronic HCV infection~Exclusion Criteria:~* Has an infection/co-infection with non-genotype 4 HCV~* Has a co-infection with Human Immunodeficiency Virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening).~* Has any of the following laboratory abnormalities:~  1. Platelet count \<90,000/mm3;~ 2. Absolute neutrophil count (ANC) \<1500 cells/mm3 (Blacks: \<1200 cells/mm3);~ 3. Hemoglobin \<12 g/dL for women and \<13 g/dL for men;~ 4. Creatinine \>1.5 mg/dL;~ 5. ALT and/or AST \>10 x upper limit of normal (ULN);~ 6. Total serum bilirubin \>1.5 x ULN;~ 7. Alpha-fetoprotein \[AFP\] \>50 ng/mL;~ 8. Albumin plasma concentration \<3.5 g/dL;~ 9. Prothrombin time (PT) expressed as international normalized ratio (INR) \>1.5. Note: retesting of abnormal laboratory values that leads to exclusion will be allowed once using an unscheduled visit during the screening period to assess eligibility.~* Used disallowed concomitant therapy~* Has evidence of hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfills all inclusion criteria for the PS0014 \[NCT03598790\] study~* Subject is considered reliable and capable of adhering to the DV0002 protocol (eg, able to understand and complete questionnaires, willing to self-inject, able to use investigational device according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator~Exclusion Criteria:~* Subjects are not permitted to enroll in DV0002 if any of the PS0014 \[NCT03598790\] study exclusion criteria are met

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab-SS (Type: EXPERIMENTAL): Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
- Bimekizumab-AI (Type: EXPERIMENTAL): Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have successfully completed one of the following studies: XP052 (110963 \[NCT00298623\]), XP053 (111460 \[NCT00365352\]), XP081 (111462 \[NCT01332305\]), and XP083 (111463 \[NCT01332318\]).~Exclusion Criteria:~* Subjects who, in the opinion of the Investigator, would be non-compliant with the study visit schedule, procedures, or medication administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XP13512 (GEn) (Type: EXPERIMENTAL): 1200 mg XP13512, orally, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proved nasopharyngeal carcinoma.~* T4NxM0 or TxN3M0 disease by UICC/AJCC 1997 staging system. (30)~* Eastern Cooperative Oncology Group performance status \< 2.~* A leukocyte count ≥3750/mL, Hb ≥ 10 g/dL, and a platelet count ≥100,000/mL.~* A serum bilirubin level \< 1.5 mg/dL, serum creatinine level \< 1.6 mg/dL or creatinine clearance \> 60 mL/min.~* Age less than 70 years old~* An informed consent signed.~Exclusion Criteria:~* Evidence of metastatic disease.~* Presence of another malignancy other than treated squamous/basal cell carcinoma of the skin.~* Presence of uncontrolled hypertension, poorly controlled heart failure.~* Presence of active infection.~* Patients who have been or are being treated with chemotherapy, radiotherapy, immunotherapy, or other experimental therapies.~* Women who test positive for pregnancy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A arm (Type: ACTIVE_COMPARATOR): CCRT
- B arm (Type: EXPERIMENTAL): Induction/CCRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult nephrotic patients, at least 18 years of age~2. Diagnosis of focal segmental glomerulosclerosis (FSGS), resistant or relapsing minimal change disease with failure to achieve a sustained partial or complete remission of the nephrotic syndrome after therapy with at least two first line therapies: corticosteroids and at least one other immunosuppressive regimen~3. Diagnosis of membranous nephropathy with failure to achieve a sustained partial or complete remission of the nephrotic syndrome after therapy with at least two first line therapies: either the Ponticelli protocol of alternating months of pulse steroids followed by oral steroids and then an alkylating agent with each regimen repeated for six full months of therapy or a calcineurin inhibitor, cyclosporine or tacrolimus, and at least one other therapy~4. Diagnosis of immunoglobulin A nephropathy (IgAN) with persistent nephrotic range proteinuria in patients on ACE inhibition or angiotension receptor blockers (ARB) therapy to reduce proteinuria~5. Willing and able to sign informed consent~6. Patients of childbearing age must agree to use birth control~Exclusion Criteria:~1. Patients under 18 years of age~2. Patients unable to sign informed consent~3. Patients having received rituximab or another monoclonal antibody within 6 months of the trial~4. Patients of childbearing age who refuse to use birth control~5. Patients with an estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2~6. Patients with other renal diseases (e.g. diabetic nephropathy, renal vascular disease) that would interfere with interpretation of the study.~7. Patients with comorbid conditions that would interfere with completion of the trial (malignancies, congestive heart failure (CHF), recent myocardial infarction).~8. Patients with known contraindications to the use of H.P. ACTHAR Gel, including: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, and allergies to pork or pork products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acthar gel (Type: EXPERIMENTAL): Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Composites and Urinary Bisphenol-A Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 3-16 (\<17) years at enrollment.~* 2+ posterior teeth with caries requiring restorations treatable by composite.~* Toilet-trained (not using diapers, pull-ups, or training pants during day or night).~Exclusion Criteria:~* Medical conditions that would render the subject physically unable to provide urine samples.~* Guardian is not proficient in spoken English or Spanish language~* Child is aged 8.0 years or older and not proficient in spoken English or Spanish language~* Living \>35 miles outside of the dental clinic or the NERI office (Watertown MA)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Composite (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete